ADC Therapeutics appoints Joseph Camardo, MD, as Head of Medical Affairs

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors, announced the appointment of Joseph Camardo, MD, as Head of Medical Affairs. Dr. Camardo will develop and implement post-approval research, education and physician support activities to ensure optimal medical impact for loncastuximab tesirine (ADCT-402) for patients with B-cell non-Hodgkin lymphoma.

"We are thrilled to welcome Joe to ADC Therapeutics' senior management team and look forward to his leadership and insights as we embark on an exciting year, during which we will submit a BLA to the U.S. Food and Drug Administration for loncastuximab tesirine, conduct launch readiness activities and continue advancing our pipeline of novel ADCs," said Chris Martin, Chief Executive Officer of ADC Therapeutics.

Dr. Camardo joins ADC Therapeutics from Celgene Corporation, where he was most recently Senior Vice President of Celgene Global Health after having served as Senior Vice President of Global Medical Affairs and Corporate Medical Operations. Prior to Celgene, Dr. Camardo was Senior Vice President of Clinical Development and Medical Affairs at Forest Research Institute and spent more than 20 years at Wyeth Research before its acquisition by Pfizer. At Wyeth, he held roles including Senior Vice President of Global Medical Affairs and Senior Vice President of Clinical Research and Development. He oversaw the development of the first-ever approved antibody drug conjugate Mylotarg (gemtuzumab ozogamicin) for acute myeloid leukemia, the early development of Besponsa (inotuzumab ozogamicin) for acute lymphoblastic leukemia, Torisel (temsirolimus) for renal cell carcinoma and other oncology development programs.

"Joe's expertise in every stage of oncology drug development, from R&D to global product launches, and his extensive experience leading the medical affairs function for global biopharma companies will be integral to ADC Therapeutics," said Jay Feingold, MD, PhD, Senior Vice President and Chief Medical Officer at ADC Therapeutics.

"ADC Therapeutics' therapies have great potential for patients suffering from hematological cancers and solid tumors," said Dr. Camardo. "I'm excited to contribute to the success of the company as we advance the development and prepare for the commercialization of novel ADCs."